Robert Roscigno, PhD, joined Gossamer Bio in July 2020 and has served as Senior Vice President of Clinical Development, Pulmonary Vascular Disease, since September 2024. He is the clinical lead of the Seralutinib program. Dr. Roscigno possesses over 27 years of drug development experience related to pulmonary hypertension and has extensive expertise in developing novel drug/device delivery systems (inhalation, intravenous, subcutaneous) for the pharmaceutical market. He is a co-inventor on multiple U.S. patents and has published numerous articles in scientific journals.

Prior to his tenure at Gossamer Bio, Dr. Roscigno held the position of Senior Vice President of Product Development and served as the program lead for LIQ861 (YUTREPIA™) at Liquidia Corporation. In this role, he was responsible for advancing the company’s lead product from preclinical testing to NDA submission. Before joining Liquidia in September 2015, Dr. Roscigno served as Executive Vice President of Global Clinical Affairs at GeNO LLC (now VERO Biotech), where he led the clinical development team working on a novel nitric oxide delivery system (GENOSYL®). Prior to his role at GeNO, which began in 2009, Dr. Roscigno was the President and Chief Operating Officer of Lung Rx, Inc., where he successfully guided the company’s lead product, Tyvaso®, through Phase 3 development.

From 1997 to 2007, Dr. Roscigno held various leadership positions at United Therapeutics Corporation, contributing significantly to the company’s growth from a start-up to a multi-billion-dollar global entity. As one of the principal scientific developers of Remodulin™ for the treatment of pulmonary arterial hypertension, he played a key role in its successful development and worldwide commercialization.

Dr. Roscigno holds a Ph.D. in Cell and Molecular Biology from Duke University and a B.S. in Biology from Trinity College.